Literature DB >> 33970262

Extended-Release Buprenorphine and Its Evaluation With Patient-Reported Outcomes.

Wilson M Compton1, Nora D Volkow1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33970262     DOI： 10.1001/jamanetworkopen.2021.9708

Source DB:  PubMed          Journal:  JAMA Netw Open        ISSN： 2574-3805


× No keyword cloud information.
  2 in total

1.  Association Between Buprenorphine Treatment Gaps, Opioid Overdose, and Health Care Spending in US Medicare Beneficiaries With Opioid Use Disorder.

Authors:  Jason B Gibbons; Jeffrey S McCullough; Kara Zivin; Zach Y Brown; Edward C Norton
Journal:  JAMA Psychiatry       Date:  2022-10-05       Impact factor: 25.911

2.  Barriers and facilitators to opioid agonist treatment (OAT) engagement among individuals released from federal incarceration into the community in Ontario, Canada.

Authors:  Cayley Russell; Michelle Pang; Frishta Nafeh; Shanna Farrell Macdonald; Dena Derkzen; Jürgen Rehm; Benedikt Fischer
Journal:  Int J Qual Stud Health Well-being       Date:  2022-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.